Cellectis S.A. - American Depositary Shares — Quarterly Financial Data (NASDAQ:CLLS) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics Dividends

Quarterly Annual

Dividends per share — — Dividend yield % — — Payout ratio % — —

Cellectis S.A. - American Depositary Shares

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.

Haberler

Jefferies startet Coverage für Cellectis mit Kaufempfehlung und hohem Kurspotenzial

Jefferies assumes coverage on Cellectis stock with Buy rating

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Brunswick (NYSE:BC), Cellectis (NASDAQ:CLLS)

Cellectis: Clear Street startet Aktie mit "Buy" und sieht fast 93 % Kurspotenzial

Clear Street initiates Cellectis stock with Buy rating on CAR-T potential

Cellectis: Showcasing Encouraging Data, But Still Early To Make A Run Like This (CLLS)

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Allogene Therapeutics (NASDAQ:ALLO), Cellectis (NASDAQ:CLLS)

Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Argo Blockchain (NASDAQ:ARBK), Ascent Solar Technologies (NASDAQ:ASTI)

Allogene: Aktie steigt nach positivem Schiedsspruch zu Therapierechten

Allogene sichert sich Kontrolle über Krebstherapie durch Schiedsspruch

Allogene stock rises after favorable arbitration ruling reaffirms therapy rights

Schiedsspruch beendet Lizenzvereinbarung zwischen Cellectis und Servier teilweise